Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

  • Post published:August 3, 2021
  • Post category:Press Release
Read more about the article MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

  • Post published:August 3, 2021
  • Post category:Press Release
Read more about the article Psychedelic Bulletin: MindMed Initiates DMT Trial; COMPASS Appoints CMO; Field Trip Lists on NASDAQ

Psychedelic Bulletin: MindMed Initiates DMT Trial; COMPASS Appoints CMO; Field Trip Lists on NASDAQ

  • Post published:July 30, 2021
  • Post category:Psychedelic Bulletin
Read more about the article Red Light Holland Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements

Red Light Holland Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements

  • Post published:July 30, 2021
  • Post category:Press Release
Read more about the article Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

  • Post published:July 30, 2021
  • Post category:Press Release
Read more about the article Small Pharma Reports First Fiscal Quarter 2021 Highlights

Small Pharma Reports First Fiscal Quarter 2021 Highlights

  • Post published:July 30, 2021
  • Post category:Press Release
Read more about the article Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing

Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing

  • Post published:July 29, 2021
  • Post category:Press Release
Read more about the article Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

  • Post published:July 29, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Acquires Five Addiction Clinics in Alberta

Levitee Labs Acquires Five Addiction Clinics in Alberta

  • Post published:July 29, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Acquires Three Specialized Alberta Pharmacies

Levitee Labs Acquires Three Specialized Alberta Pharmacies

  • Post published:July 29, 2021
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More